Page results
-
This page has been written for parents, carers and family members who are acting as carers and comforters for children and young people having radioactive mIBG treatment.
-
All GPs are now welcome to use our national Infectious & Tropical Disease Advice and Guidance function on the e-referral system (NHS e-RS)
-
Our outpatient clinics will remain predominantly virtual throughout the COVID-19 pandemic. Please continue to refer via the NHS e-referral service.
-
This information is for UCLH patients with cancer or a blood condition who are being offered a PICC (peripherally inserted central catheter).
-
This page provides information about the WEB device and how it is used to treat cerebral (brain) aneurysms
-
UCLH has recruited the first European participant to a trial looking at treating non-hospitalised Covid-19 patients with the drug remdesivir.
-
This page explains what you can expect after you have been referred to the Lymphoedema Service at University College London Hospitals (UCLH) for a face-to-face appointment.
-
The world’s first COVID-19 vaccine study researching alternating doses and intervals of approved vaccines is taking place at UCLH.
-
In a major study involving UCLH a third of people who took a new drug for treating obesity lost more than one-fifth of their total body weight.
-
A front page story and patient case study highlight SUMMIT Study early diagnosis outcomes.
File results
-
FOI/2022/0794 - Communication personnel and communication spend
-
FOI/2022/0795 - Mobile software (communications, chat, photo) used by the Trust
-
FOI/2022/0796 - Procedures performed for various bone biopsies/ treatments
-
FOI/2022/0797 - Information Governance and Corporate Governance personnel
-
FOI/2022/0800 - Day unit/ outpatient unit for haematology patients
-
FOI/2023/0174 - Integration Engine (IE) within Trust's IT estate
-
FOI/2023/0182 - Data privacy compliance tools
-
FOI/2023/0180 - Treatment guidelines for chronic kidney disease/ diabetic kidney disease
-
FOI/2023/0175 - Treatment for Myelofibrosis
-
FOI/2023/0187 - Treatment for urothelial and colorectal cancer